Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Kiladjian, Jean-Jacques  [Clear All Filters]
2015
Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti A-M, Sebert M, Boissel N, Robin M, Vey N, Kiladjian J-J, et al. Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2015.
Kiladjian J-J. Current Therapies and Their Indications for the Philadelphia-Negative Myeloproliferative Neoplasms. Am Soc Clin Oncol Educ Book. 2015;35:e389-e396.
2018
Guadall A, Lesteven E, Letort G, Toor SAwan, Delord M, Pognant D, Brusson M, Verger E, Maslah N, Giraudier S, et al. Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features. Thromb Haemost. 2018.
Godfrey AL, Campbell PJ, Maclean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, et al. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. J Clin Oncol. 2018:JCO2018788414.
2021
Mosca M, Hermange G, Tisserand A, Noble RJohn, Marzac C, Marty C, Le Sueur C, Campario H, Vertenoeil G, El-Khoury M, et al. Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms. Blood. 2021.
Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian J-J, de Castro C, et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021;384(11):1028-1037.
Alvarez-Larran A, Sant'Antonio E, Harrison C, Kiladjian J-J, Griesshammer M, Mesa R, Ianotto JChristophe, Palandri F, Hernández-Boluda JCarlos, Birgegård G, et al. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematol. 2021;8(9):e658-e665.
2022
Passamonti F, Harrison CN, Mesa RA, Kiladjian J-J, Vannucchi AM, Verstovsek S. Anemia in myelofibrosis: current and emerging treatment options. Crit Rev Oncol Hematol. 2022:103862.
Marchetti M, Vannucchi AMaria, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Alvarez-Larran A, De Stefano V, Guglielmelli P, Palandri F, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):e301-e311.
de Latour RPeffault, Szer J, Weitz IC, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian J-J, de Castro CM, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9(9):e648-e659.
2023
Maslah N, Benajiba L, Giraudier S, Kiladjian J-J, Cassinat B. Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. Leukemia. 2023.
Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, Palandri F, Iurlo A, De Stefano V, Kiladjian J-J, et al. Incidence of blast phase in myelofibrosis according to anemia severity. EJHaem. 2023;4(3):679-689.
2024
Harrison CN, Kiladjian J-J, Koschmieder S, Passamonti F. Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives. Cancer. 2024.
Kiladjian J-J, Marin FFerrer, Al-Ali HKathrin, Alvarez-Larran A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan A-M, et al. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. 2024.